Washington University School of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).
Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.
Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.
Top-decile sponsor footprint
Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,502 total, page 5 of 31
Chromosome 9 P Minus Syndrome
NCT04586400
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
NCT03141021
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
NCT03128996
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
NCT02994433
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT02476786
Cognitive Biomarkers in Pediatric Brain Tumor Patients
NCT02914067
Investigations of Dementia in Parkinson Disease
NCT02763683
Aging, Geriatric Syndromes and Clonal Hematopoiesis
NCT02604563
Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy
NCT02559752
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
NCT02841553
Clinical Outcomes for Deep Brain Stimulation
NCT03992625
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
NCT07493460
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
NCT06844669
Evaluating the Human Immune Response to the JYNNEOS Vaccine
NCT06366672
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573
Resettled Refugee Families for Healing
NCT06176638
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
NCT05813327
Decreasing Emergence Delirium With Personalized Music
NCT06236477
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT06141031
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05944562
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
NCT05980000
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT05743595
Multi-modal Imaging of Myofascial Pain
NCT06036524
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
NCT05377827
Sing For Your Saunter Part 2 R33
NCT06115382
Recovery Control Tower Feasibility Pilot
NCT06732921
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
NCT05838560
Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer
NCT05785845
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
NCT05616624
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05628363
Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine
NCT05738213
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
NCT05464329
Early Outcomes of MAKO Medial Unicompartmental Knee Arthroplasty
NCT05736601
Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
NCT05731440
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
NCT05410418
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
NCT05030441
Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers
NCT05689983
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
NCT04397003
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
NCT05044039
RYSE Family-based Behavioral Treatment for Childhood Obesity
NCT05212155
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT04743505
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
NCT05269394
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
NCT04685590
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
NCT05111262
Everyday Memory Impairment in PD-related Cognitive Decline
NCT04474379
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
NCT04831320
Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial
NCT04793412
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 332 |
| Phase 2 | 237 |
| Phase 3 | 40 |
| Phase 4 | 58 |
Therapeutic Areas
What is open in the Washington University School of Medicine pipeline
214 recruiting of 1,502 indexed (14% open); 919 completed (61%).
Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).
Top condition: Obesity (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Washington University School of Medicine: open-pipeline peers nationwide
Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,502 trials (± recruiting share)
- Yale University · 1,492 trials · 17% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Washington University School of Medicine page
1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.
- 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets.Report a data error.